Bone Biologics Corporatio... (BBLG)
NASDAQ: BBLG
· Real-Time Price · USD
2.25
-0.10 (-4.26%)
At close: Aug 15, 2025, 12:15 PM
Bone Biologics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -4.35M | -4.22M | -3.83M | -4.96M | -7.18M | -9.43M | -9.56M | -8.7M | -6.13M | -3.63M | -2.8M | -1.81M | -1.58M | -1.1M | -849K | -764.82K | -665.82K |
Interest Income | 75.44K | 55.66K | 35.74K | 16.29K | 1.57K | 1.87K | 2.25K | 1.72K | 1.29K | 731.71 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -4.26M | -4.11M | -4.14M | -5.12M | -6.11M | -8.95M | -6.51M | -5.81M | -4.51M | -1.45M | -2.52M | -1.81M | -1.83M | -1.61M | -1.89M | -1.77M | -1.66M |
Net Income | -4.26M | -4.11M | -4.14M | -5.12M | -6.11M | -8.95M | -6.51M | -5.8M | -4.5M | -1.48M | -2.56M | -1.84M | -1.87M | -1.61M | -1.89M | -1.77M | -1.66M |
Selling & General & Admin | 2.05M | 2.09M | 2.35M | 2.34M | 2.62M | 2.52M | 2.34M | 2.28M | 1.99M | 2.05M | 1.95M | 1.73M | 1.5M | 1.02M | 779.82K | 552.97K | 446.82K |
Research & Development | 2.31M | 2.13M | 1.47M | 2.62M | 4.56M | 6.91M | 7.22M | 6.41M | 4.13M | 1.58M | 857.94K | 88.53K | 72.94K | 82.04K | 69.21K | 212.09K | 219.07K |
Other Expenses | -854 | -368 | -8 | -48 | 335.00 | 443.00 | 758.00 | 521.00 | 138.00 | 30.00 | -277 | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.35M | 4.22M | 3.82M | 4.95M | 7.18M | 9.43M | 9.56M | 8.7M | 6.13M | 3.63M | 2.8M | 1.81M | 1.58M | 1.1M | 849.03K | 765.06K | 665.89K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 731.71K | 731.71K | 731.71K | 731.71K | 14.76K | 294.27K | 554.29K | 805.11K | 1.04M | 1.01M | 993.65K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -300K | -300K | -300K |
Cost & Expenses | 4.35M | 4.22M | 3.82M | 4.95M | 7.18M | 9.43M | 9.56M | 8.7M | 6.13M | 3.67M | 2.84M | 1.85M | 1.61M | 1.1M | 849.03K | 765.06K | 665.89K |
Income Tax Expense | n/a | n/a | -349 | -2.43K | -2.86K | -2.86K | -4.11K | -3.24K | -3.29K | 29.79K | 32.99K | 34.2K | 34.45K | 1.19K | 1.19K | 1.19K | 1.42K |
Shares Outstanding (Basic) | 3.18M | 2.95M | 1.75M | 1.17M | 660K | 458K | 391K | 339K | 67K | 61K | 43K | 43K | 43K | 43K | 51K | 12.13K | 12K |
Shares Outstanding (Diluted) | 3.18M | 2.95M | 1.75M | 1.17M | 660.93K | 458.98K | 391.85K | 339.31K | 67.21K | 61.06K | 43.19K | 43.13K | 43.13K | 43.13K | 51.14K | 51.14K | 12.13K |
EPS (Basic) | -6.45 | -7.44 | 43.68 | 41.15 | 36.61 | -17.28 | 18.77 | -4.56 | -10.23 | 28.98 | 120.16 | 138.43 | 108.51 | 88.50 | -140 | -137.75 | -104.38 |
EPS (Diluted) | -6.45 | -7.44 | 43.68 | 41.15 | 36.61 | -17.28 | 11.42M | 11.42M | 11.42M | 11.42M | 120.16 | 138.43 | 139.69 | 120.09 | -143.23 | -140.98 | -138.79 |
EBITDA | -4.25M | -3.1M | -1.8M | -3.94M | -4.9M | -8.16M | -5.37M | -4.51M | -3.21M | -720K | -2.5M | -1.52M | -1.28M | -804K | -849K | -764.82K | -665.82K |
EBIT | -4.35M | -4.22M | -3.83M | -4.96M | -7.18M | -9.43M | -7.38M | -6.52M | -3.94M | -1.49M | -2.54M | -1.55M | -1.31M | -804K | -849K | -764.82K | -665.82K |
Depreciation & Amortization | 47.03K | 950.56K | 2.56M | 3.69M | 6.73M | 8.97M | 9.56M | 8.69M | 5.65M | 2.51M | 1.22M | n/a | n/a | n/a | 13.00 | 26.00 | 39.00 |